| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/21/2010 | CA2739379A1 Compounds as the estrogen-related receptor modulators and the uses thereof |
| 01/21/2010 | CA2736311A1 Novel use application of sugar chain-recognizing receptor |
| 01/21/2010 | CA2731215A1 Imidazole carboxamide derivatives and their use in treatment of conditions associated with the mglur2 receptor |
| 01/21/2010 | CA2731214A1 Antisense formulation |
| 01/21/2010 | CA2731201A1 New chito-oligomer composition for medical use |
| 01/21/2010 | CA2731196A1 Benzazepine derivatives and their use as hstamine h3 antagonists |
| 01/21/2010 | CA2731130A1 Pyridazine derivatives as smo inhibitors |
| 01/21/2010 | CA2731097A1 Organic compounds |
| 01/21/2010 | CA2731067A1 Compositions and methods for treating osteoarthritis |
| 01/21/2010 | CA2731020A1 Methods of treating an overweight or obese subject |
| 01/21/2010 | CA2731008A1 Modified release formulation and methods of use |
| 01/21/2010 | CA2730975A1 Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment |
| 01/21/2010 | CA2730964A1 Imidazo [1, 2-a] pyrimidine derivatives method for the production thereof application thereof as medicaments pharmaceutical compositions and use thereof as met inhibitors |
| 01/21/2010 | CA2730959A1 Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors |
| 01/21/2010 | CA2730958A1 Novel sulphur containing lipids for use as food supplement or as medicament |
| 01/21/2010 | CA2730940A1 Methods and systems for evaluating memory agents |
| 01/21/2010 | CA2730931A1 Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use |
| 01/21/2010 | CA2730930A1 Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| 01/21/2010 | CA2730929A1 Pyridone and pyridazone analogues as gpr119 modulators |
| 01/21/2010 | CA2730890A1 Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| 01/21/2010 | CA2730876A1 Pharmaceutical formulation between jasmonates and its derivatives and nanocarries or microcarries |
| 01/21/2010 | CA2730843A1 Oxazolopyrimidines as edg-1 receptor agonists |
| 01/21/2010 | CA2730826A1 Antibacterial combination therapy for the treatment of gram positive bacterial infections |
| 01/21/2010 | CA2730806A1 Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic |
| 01/21/2010 | CA2730796A1 Aptamer against il-17 and use thereof |
| 01/21/2010 | CA2730793A1 Azole compound |
| 01/21/2010 | CA2730773A1 Methods and products for treating proliferative diseases |
| 01/21/2010 | CA2730749A1 Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors |
| 01/21/2010 | CA2730738A1 Use of hdac inhibitors for the treatment of hodgkin's disease |
| 01/21/2010 | CA2730737A1 Immunogenic amphipathic peptide compositions |
| 01/21/2010 | CA2730734A1 Deuterated benzylbenzene derivatives and methods of use |
| 01/21/2010 | CA2730708A1 Selective hydroxamic acid based mmp-12 and mmp-13 inhibitors |
| 01/21/2010 | CA2730665A1 Dosage form containing a statin |
| 01/21/2010 | CA2730641A1 Rna antagonists targeting gli2 |
| 01/21/2010 | CA2730615A1 Pacap signaling pathway modulators for treating inflammatory skin diseases with a neurogenic component, and more particularly rosacea and composition containing them |
| 01/21/2010 | CA2730612A1 Composition of branched maltodextrins and eukaryotic organisms having a polysaccharide wall, used in the field of well-being |
| 01/21/2010 | CA2730610A1 Bicyclic heterocycle derivatives and their use as gpcr modulators |
| 01/21/2010 | CA2730607A1 Process for producing glycosaminoglycans |
| 01/21/2010 | CA2730606A1 Bicyclic heterocycle derivatives and methods of use thereof |
| 01/21/2010 | CA2730596A1 Stigmine conjugates for substance use disorders |
| 01/21/2010 | CA2730593A1 Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
| 01/21/2010 | CA2730534A1 Formulation for improving the bioavailability of a hydrophobic molecule |
| 01/21/2010 | CA2730516A1 Novel tricyclic derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| 01/21/2010 | CA2730493A1 Modulators of acetyl-coenzyme a carboxylase and methods of use thereof |
| 01/21/2010 | CA2730477A1 Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases |
| 01/21/2010 | CA2730397A1 Substituted indolyl and indazolyl derivatives and uses thereof |
| 01/21/2010 | CA2730390A1 Aminotetrahydroindazoloacetic acids |
| 01/21/2010 | CA2730331A1 Heterocyclic derivatives that are used in the treatment of neurodegenerative diseases |
| 01/21/2010 | CA2730287A1 Pharmaceutical formulations containing dopamine receptor ligands |
| 01/21/2010 | CA2730281A1 Novel indole derivative having, carbamoyl group, ureido group and substituted oxy group |
| 01/21/2010 | CA2730225A1 Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis |
| 01/21/2010 | CA2730218A1 Method for manufacturing medicinal compounds containing dabigatran |
| 01/21/2010 | CA2730190A1 Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer |
| 01/21/2010 | CA2730059A1 Tetrahydrocinnolines as 11 beta hsd1 inhibitors for diabetes |
| 01/21/2010 | CA2730056A1 Novel heterocyclyl compounds for treatment of cardiovascular disease |
| 01/21/2010 | CA2730050A1 Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer |
| 01/21/2010 | CA2729990A1 New chemical compounds |
| 01/21/2010 | CA2729986A1 New chemical compounds |
| 01/21/2010 | CA2729965A1 Fused heterocyclyc inhibitor compounds |
| 01/21/2010 | CA2729909A1 Imidazolyl pyrimidine inhibitor compounds |
| 01/21/2010 | CA2729606A1 Alpha7 nicotinic acetylcholine receptor inhibitors |
| 01/21/2010 | CA2729597A1 Method of treating traumatic brain injury |
| 01/21/2010 | CA2729212A1 Compounds and methods for modulating g protein-coupled receptors |
| 01/21/2010 | CA2729207A1 Composition of soluble indigestible fibre and of microalgae used in the well-being field |
| 01/21/2010 | CA2729056A1 Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
| 01/21/2010 | CA2728915A1 Benzyloxy anilide derivatives useful as potassium channel modulators |
| 01/21/2010 | CA2728830A1 Protein kinase inhibitors |
| 01/21/2010 | CA2728729A1 Protein kinase inhibitors |
| 01/21/2010 | CA2728636A1 Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents |
| 01/21/2010 | CA2728616A1 Piperidyl acrylamide antogonists of ccr2 |
| 01/21/2010 | CA2728562A1 Methods for treating multiple sclerosis using antisense oligonucleotides |
| 01/21/2010 | CA2728467A1 Compositions and methods for inhibiting expression of tgf-beta receptor genes |
| 01/21/2010 | CA2728311A1 Aminotetrahydroindazoloacetic acids |
| 01/21/2010 | CA2728228A1 Oxindolyl inhibitor compounds |
| 01/21/2010 | CA2728225A1 Methods for determining sensitivity to aminoflavones |
| 01/21/2010 | CA2728097A1 Methods of preparing imidazole-based bicyclic compounds |
| 01/21/2010 | CA2728095A1 Pyrazole-containing tricyclic compounds as antagonists of an ep1 receptor |
| 01/21/2010 | CA2728094A1 Solid forms of (1r,2s,3r)-1-(2-(isoxazol-3-yl)-1h-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use |
| 01/21/2010 | CA2727769A1 Novel compounds active as muscarinic receptor antagonists |
| 01/21/2010 | CA2727174A1 Aryl gpr119 agonists and uses thereof |
| 01/21/2010 | CA2726460A1 Novel phenyl-imidazopyridines and pyridazines |
| 01/21/2010 | CA2725598A1 Antineoplastic combinations containing hki-272 and vinorelbine |
| 01/21/2010 | CA2725512A1 Novel phenylimidazopyrazines |
| 01/21/2010 | CA2720538A1 Solid states of o-desmethylvenlafaxine salts |
| 01/21/2010 | CA2690838A1 Anti-cancer composition comprising microrna molecules |
| 01/20/2010 | EP2145957A1 Compositions for enhancing delivery of double-stranded RNA to regulate gene expression in mammalian cells |
| 01/20/2010 | EP2145897A2 Therapeutic methods and compositions based on serrate proteins and nucleic acids |
| 01/20/2010 | EP2145891A1 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
| 01/20/2010 | EP2145889A1 Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes |
| 01/20/2010 | EP2145888A1 Deazapurine derivatives as HSP90-Inhibitors |
| 01/20/2010 | EP2145887A2 Substituted 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indoles, methods for the production and use thereof |
| 01/20/2010 | EP2145886A1 Twelve-membered cyclomacrolactam derivative |
| 01/20/2010 | EP2145884A1 Indoledione derivative |
| 01/20/2010 | EP2145883A1 Dibenzyl lipoic acid derivatives and their use in treatment of disease |
| 01/20/2010 | EP2145881A1 Antiarrhythmic precursor compounds, methods of synthesis and methods of use |
| 01/20/2010 | EP2145879A1 Pyrazine derivatives, methods of use, and methods for preparing same |
| 01/20/2010 | EP2145878A2 Aurora Kinase inhibitors |
| 01/20/2010 | EP2145877A2 Aurora Kinase inhibitors |
| 01/20/2010 | EP2145873A1 New compounds with activity that protects against the action of toxins and viruses in intracellular action mode |
| 01/20/2010 | EP2145629A2 Use of neurotoxin therapy for treatment of urologic and related disorders |